Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma

NCT03683576 is registered in ClinicalTrials.gov with GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. as lead sponsor.

NCT NCT03683576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03683576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 22, 2018
Completion date
August 18, 2020
Enrollment
481 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

asthma